Table 1.
Clinical characteristics at baseline (1 week before starting chemotherapy) (n = 169)
| Characteristics | N (%) |
|---|---|
| Age, years: mean ± SD (range) | 54 ± 11 (25;80) |
| BMI | |
| Normal weight/underweight | 102 (60.4) |
| Overweight | 41 (24.3) |
| Obesity | 26 (15.4) |
| Mean ± SD (range) | 24.9 ± 4.8 (15.9;41.2) |
| Menopausal status | |
| Premenopausal | 68 (40) |
| Postmenopausal | 101 (60) |
| Pathological tumor stage | |
| 0 | 19 (11) |
| 1 | 82 (49) |
| ≥2 | 68 (40) |
| Pathological nodal stage | |
| 0 | 95 (56) |
| ≥1 | 74 (44) |
| Histological type | |
| No special type | 153 (91) |
| Others | 16 (9) |
| Estrogen receptor | |
| Positive | 118 (70) |
| Negative | 51 (30) |
| Progesterone receptor | |
| Positive | 99 (59) |
| Negative | 70 (41) |
| Grading | |
| G1 or G2 | 20 (12) |
| G3 | 147 (87) |
| Unknown | 2 (1) |
| Ki-67 labeling index | |
| <20% | 31 (18) |
| ≥20% | 138 (82) |
| HER2 | |
| Positive | 67 (40) |
| Negative | 102 (60) |
| Chemotherapy | |
| Adjuvant | 130 (78) |
| Neo-adjuvant | 39 (22) |
| Chemotherapy regimen | |
| Anthracyclines | 29 (17) |
| Taxanes | 22 (13) |
| Sequential | 109 (65) |
| Others | 9 (5) |
| Hormone therapy | |
| None | 56 (33) |
| Tamoxifen | 13 (8) |
| Aromatase inhibitors | 83 (49) |
| LHRH agonist + tamoxifen | 6 (4) |
| LHRH agonist + aromatase inhibitors | 11 (6) |
| Surgery treatment | |
| Breast-conserving | 91 (54) |
| Mastectomy | 78 (46) |
G1 well-differentiated tumor, G2 moderately differentiated tumor, G3 undifferentiated tumor, HER2 human epidermal growth factor receptor 2, LHRH luteinizing hormone-releasing hormone